TNF-alpha processing inhibitor

Drug Profile

TNF-alpha processing inhibitor

Alternative Names: TAPI - Amgen; TNF-alpha protease enzyme inhibitor; Tumour necrosis factor-alpha protease inhibitor

Latest Information Update: 23 Jun 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories
  • Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 23 Jun 2000 No-Development-Reported for Inflammation in USA (Unknown route)
  • 21 Apr 1999 Immunex has exclusively licensed its TNF-alpha converting enzyme technology to Wyeth-Ayerst
  • 14 Feb 1997 Preclinical development for Inflammation in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top